Spanish pharmaceutical company Kymos and German CRO Prolytic today announced the completion of a strategic merger into "Kymos Group," a new pan-European conglomerate with the hopes of providing innovative industry solutions.
Kymos claims this merger will allow the company to expand its interests in the biologics and advanced therapies markets and allow it to expand to three more local sites across Europe.
They said it will allow them to expand their reach into research into innovative large and small molecules, generics, biosimilars, antibodies, anti-drug antibodies (ADA), antibody-drug conjugates, hormones, enzymes and nucleic acids.
According to a statement issued by the companies, Prolytic has also gained expertise in mRNA technologies, which are primarily used in some of the most advanced Covid-19 vaccines being developed in Europe.
This hints that their combined expertise in advanced therapies and RNA technologies could help combat the ongoing pandemic.
The partnership will also include recent Kymos acquisition, the Italian company Pharmaprogress, which they claim will help them keep to their current standard of provided bespoke and quality services to their clients.
They hope the merger will give them resources and expertise needed to cover a wider array of topics and a larger portfolio of clients.
Dr Dorothee Krone, marketing director at Prolytic, said: "Today's market wants full-service providers and one-stop-solutions. With this merger we will be able to think globally and act locally, providing out clients with a reliable, turstworthy and much-imrpvoed service.
"Small and mid-sized companies feel comfortable working with us. Kymos can help us cover the whole life science cycle and we can now offer a much more diverse range of services than we have ever been able to in the past."
Kymos CEO, Joan De Puig, said that Prolytics has the required expertise in various fields their merger needs to truly innovate the market.
He added: "The knowledge that Prolytics has regarding DNA and RNA is a key scientific element of the advanced therapies services market that Kymos is entering.
"The merger is gives us the opportunity to increase our service offering, stengthen the emerging therapies market and create a multinational and multidisciplinary company. We are very much looking forward to this new phase in the company's history."
With the coalition, Kymos now has three sites in Europe: Barcelona, Ancona and Frankfurt. Under the agreement, the company's will keep their names, as will the management of the Frankfurt branch. However, staff numbers are expected to increase in the German office.
The merger is expected to formulate a funding initiatives to best allow them to allocate spending on cutting-edge equipment.
The group hope to expand their influence into Asia in the next phase of their plan.
Back to Homepage
Back to Healthcare